Lantheus Holdings, Inc.

LNTH

US5165441032

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 03:28:27 2024-05-15 pm EDT			5-day change	1st Jan Change
79.4 ^USD	+0.88%		+6.23%	+27.66%

May. 03	Truist Raises Lantheus Holdings' PT to $94 From $82 After 'Solid' Q1 Beat, Keeps Buy Rating	MT
May. 02	Lantheus Shares Rise After Reporting Higher Q1 Adjusted Earnings, Revenue; 2024 Guidance Raised	MT

Lantheus Holdings, Inc. Elevates Robert J. Marshall, Jr. as Treasurer

August 28, 2023 at 04:11 pm EDT

The Board of Directors of Lantheus Holdings, Inc. elevated the level of Robert J. Marshall, Jr.?s role as Treasurer of the Company, effective as of August 28, 2023.

Latest news about Lantheus Holdings, Inc.

Truist Raises Lantheus Holdings' PT to $94 From $82 After 'Solid' Q1 Beat, Keeps Buy Rating	May. 03	MT
Lantheus Shares Rise After Reporting Higher Q1 Adjusted Earnings, Revenue; 2024 Guidance Raised	May. 02	MT
Lantheus to Seek M&A Opportunities	May. 02	CI
Transcript : Lantheus Holdings, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Lantheus Holdings, Inc. Provides Revenue Guidance for the Second Quarter of Fiscal Year 2024	May. 02	CI
Lantheus Holdings, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024	May. 02	CI
(LNTH) LANTHEUS HOLDINGS Sees Q2 EPS Range $1.81 - $1.86	May. 02	MT
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q1 Revenue $370M	May. 02	MT
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q1 EPS $1.69	May. 02	MT
Lantheus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
B. Riley Raises Price Target on Lantheus Holdings to $99 From $95, Keeps Buy Rating	Apr. 18	MT
Lantheus Holdings Insider Sold Shares Worth $262,005, According to a Recent SEC Filing	Mar. 07	MT
Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc. and other investors	Mar. 05	CI
Lantheus Holdings Says FDA Approves Expanded Use of Definity in Pediatric Patients	Mar. 04	MT
Lantheus Holdings, Inc. Announces the FDA Approval of Definity (Perflutren Lipid Microsphere) for Pediatric Patients	Mar. 04	CI
Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors	Mar. 03	CI
Lantheus Names Amanda Morgan Chief Commercial Officer	Feb. 28	MT
Truist Adjusts Price Target on Lantheus Holdings to $82 From $80, Maintains Buy Rating	Feb. 26	MT
Sector Update: Health Care Stocks Advance Pre-Bell Thursday	Feb. 22	MT
Lantheus Holdings Q4 Adjusted Earnings, Revenue Climb; Issues Q1, Full Year Guidance; Shares Rise	Feb. 22	MT
Transcript : Lantheus Holdings, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
(LNTH) LANTHEUS HOLDINGS Forecasts Q1 EPS Range $1.50 - $1.54	Feb. 22	MT
(LNTH) LANTHEUS HOLDINGS Forecasts Fiscal Year 2024 EPS Range $6.50 - $6.70	Feb. 22	MT
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q4 Revenue $354M	Feb. 22	MT
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q4 EPS $1.75	Feb. 22	MT

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Lantheus Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

78.7 USD

Average target price

104.9 USD

Spread / Average Target

+33.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
LANTHEUS HOLDINGS, INC.	+27.66%	5.45B
BIOMÉRIEUX	-4.62%	12.18B
DIASORIN S.P.A.	+8.48%	5.96B
AUTOBIO DIAGNOSTICS CO., LTD.	-6.28%	4.34B
10X GENOMICS, INC.	-53.04%	3.18B
ANDON HEALTH CO., LTD.	+12.93%	2.75B
MYRIAD GENETICS, INC.	+29.86%	2.3B
VITROLIFE AB	-3.80%	2.28B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-4.64%	1.92B
SANSURE BIOTECH INC.	+2.20%	1.61B

Diagnostic & Testing Substances